Home > Rheumatology > ACR 2019 > Spotlight on Rheumatoid Arthritis > Filgotinib promising in RA patients naïve to methotrexate

Filgotinib promising in RA patients naïve to methotrexate

Presented By
Prof. Rene Westhovens, University of Leuven, Belgium
Conference
ACR 2019
Trial
Phase 3, FINCH 3
The selective Janus kinase (JAK)1 inhibitor filgotinib induced clinically meaningful responses with high patient rates achieving the study endpoint [1]. Filgotinib, the orally administered, selective inhibitor of JAK1 has shown good efficacy and was well tolerated for the treatment of rheumatoid arthritis (RA) in phase 2 and 3 studies evaluating patients with prior inadequate response to biologics or as add-on to methotrexate [2,3]. The phase 3 FINCH 3 trial, conducted by Prof. Rene Westhovens (University of Leuven, Belgium) and his colleagues, now investigated efficacy and safety of filgotinib as monotherapy or in combination with methotrexate in methotrexate-naïve RA patients. At screening, patients had an ACR functional class 1-3, swollen joint count in 66 joints (SJC66) ≥6, and 68‐joint tender joint count (TJC68) ≥6. A total of 1,249 randomised patients received one of the study drug regimens: group A, filgotinib 200 mg plus methotrexate; group ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on